Respiratory Infectious Disease Epidemiology and Control

A special issue of Tropical Medicine and Infectious Disease (ISSN 2414-6366). This special issue belongs to the section "Infectious Diseases".

Deadline for manuscript submissions: 28 February 2025 | Viewed by 1625

Special Issue Editors


E-Mail Website
Guest Editor
WHO Collaborating Centre for Infectious Disease Epidemiology and Control, Division of Epidemiology & Biostatistics, School of Public Health, Faculty of Medicine, The University of Hong Kong, 1/F Patrick Manson Building (North Wing), 7 Sassoon Road, Hong Kong
Interests: infectious diseases epidemiology; transmission dynamics; prediction and forecast; environmental epidemiology; mitigation and control of epidemics; biostatistics; public health
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Biostatistics, Epidemiology and Environmental Health Sciences, Jiann-Ping Hsu College Public Health, Georgia Southern University, PO Box 7989, Statesboro, GA 30460, USA
Interests: statistical methods in diagnostic accuracy; mathematical modeling in infectious diseases; Bayesian data analysis; machine learning
Department of Biostatistics, School of Public Health, Southern Medical University, Guangzhou 510515, China
Interests: infectious diseases; epidemiology; biostatistics; time series; evaluation of public health intervention

Special Issue Information

Dear Colleagues,

Respiratory infectious diseases pose a significant global health burden, accounting for many associated infections and high severity, highlighting the continuous need for effective, proactive, and timely interventions to control or mitigate the spread of diseases. These interventions, through public health and social measures (PHSMs) and vaccination schemes, were found to have clear data-driven capabilities in mitigating respiratory viruses, including influenza, respiratory syncytial virus (RSV), hand-foot-and-mouth disease (HFMD) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

The detailed data on the recent COVID-19 pandemic have raised several research questions at various levels of infectious disease epidemiology and modeling. At the parametric level, it is highlighted with regard to the improvement in the inference of epidemiological parameters and their time-varying characteristics across the outbreak’s span. Such temporal parametric information could allow us to assess the impacts of these PHSMs better and, thus, provide better real-time intervention policies. Furthermore, the epidemiological dynamics and the characteristics of these respiratory viruses would be interesting to assess during the post-COVID-19 pandemic period, accounting for their coexistence and co-circulation.

In this Special Issue, we welcome submissions of studies covering topics including, but not limited to, the epidemiology and transmission dynamics of these respiratory diseases and their control strategies, impact assessments of these interventions, predictions of population immunity, and the dynamics and disease burdens of these respiratory viruses during the pre- and post-COVID-19 pandemic periods. We also welcome original research using qualitative and quantitative data, meta-analyses, or systematic reviews, as well as various types of study including brief research reports, perspectives, general commentaries, methodologies, and policy briefs.

Dr. Sheikh Taslim Ali
Dr. Jing X. Kersey
Dr. Li Li
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Tropical Medicine and Infectious Disease is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • respiratory diseases
  • epidemiology
  • dynamics
  • prediction
  • mitigation and control
  • public health policy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

14 pages, 3089 KiB  
Article
Factors Associated with IgG/IgM Levels after SARS-CoV-2 Vaccination in Patients with Head and Neck Cancer
by Wei Liao, Haoyu Liang, Yujian Liang, Xianlu Gao, Guichan Liao, Shaohang Cai, Lili Liu and Shuwei Chen
Trop. Med. Infect. Dis. 2024, 9(10), 234; https://doi.org/10.3390/tropicalmed9100234 - 8 Oct 2024
Viewed by 1143
Abstract
This study evaluated the factors influencing IgG/IgM antibody levels in 120 patients with head and neck cancer (HNC) following vaccination with inactivated SARS-CoV-2 vaccines. Each patient’s demographic and clinical data were documented, and serum IgG and IgM antibodies were detected using a commercial [...] Read more.
This study evaluated the factors influencing IgG/IgM antibody levels in 120 patients with head and neck cancer (HNC) following vaccination with inactivated SARS-CoV-2 vaccines. Each patient’s demographic and clinical data were documented, and serum IgG and IgM antibodies were detected using a commercial magnetic chemiluminescence enzyme immunoassay kit. The results indicated that while all patients had received at least one vaccine dose, 95 tested positive for IgG and 25 were negative. A higher proportion of IgG-positive patients had received three vaccine doses. Comparatively, gamma-glutamyl transferase levels were elevated in IgM-negative patients. The study further differentiated patients based on their treatment status: 46 were treatment-naive and 74 had received chemotherapy combined with immune checkpoint inhibitors (ICT) at enrollment. Despite similar baseline characteristics and time from vaccination to antibody detection, IgM positivity was significantly lower in the ICT group, with no significant difference in IgG positivity between the treatment-naive and ICT groups. A multivariable analysis identified the number of vaccine doses as an independent factor of IgG positivity, while ICT emerged as an independent risk factor for IgM positivity. Additionally, IgG titers generally declined over time, although patients with higher baseline IgG levels maintained higher titers longer. In conclusion, ICT in patients with HNC does not significantly affect IgG levels post-vaccination. However, booster vaccinations have been shown to be associated with higher IgG positivity, although these levels gradually decrease over time. Full article
(This article belongs to the Special Issue Respiratory Infectious Disease Epidemiology and Control)
Show Figures

Figure 1

Back to TopTop